Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
September 1, 1984
Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy
F K Stevenson, M J Glennie, D M Johnston, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 9, 2002
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
Alison L Tutt, Lyn O'Brien, Akmal Hussain, et al.
Molecular Immunology
|
November 1, 1991
Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors
J Greenman, A L Tutt, A J George, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1991
CD2 antigen mediated activation of the guanine nucleotide binding proteins p21ras in human T lymphocytes
J D Graves, J Downward, S Rayter, et al.
Blood
|
November 9, 2000
Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma
J Honeychurch, A L Tutt, T Valerius, et al.
Journal of Neuro-Oncology
|
July 1, 1992
The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs
S K Obukhov, M J Gennie, A L Tutt, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 17, 2011
Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration
Katie Lunnon, Jessica L Teeling, Alison L Tutt, et al.
Blood
|
March 1, 1987
Monoclonal anti-light chain idiotype as a tumor-specific probe for human neoplastic B lymphocytes
M Wrightham, A L Tutt, M J Glennie, et al.
Blood
|
October 24, 2015
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo
Thomas R W Tipton, C Ian Mockridge, Ruth R French, et al.
Journal of Immunological Methods
|
June 16, 2010
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects
G Hampson, T H Ward, J Cummings, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
September 1, 1984
Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy
F K Stevenson, M J Glennie, D M Johnston, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 9, 2002
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
Alison L Tutt, Lyn O'Brien, Akmal Hussain, et al.
Molecular Immunology
|
November 1, 1991
Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors
J Greenman, A L Tutt, A J George, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 1, 1991
CD2 antigen mediated activation of the guanine nucleotide binding proteins p21ras in human T lymphocytes
J D Graves, J Downward, S Rayter, et al.
Blood
|
November 9, 2000
Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma
J Honeychurch, A L Tutt, T Valerius, et al.
Journal of Neuro-Oncology
|
July 1, 1992
The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs
S K Obukhov, M J Gennie, A L Tutt, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 17, 2011
Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration
Katie Lunnon, Jessica L Teeling, Alison L Tutt, et al.
Blood
|
March 1, 1987
Monoclonal anti-light chain idiotype as a tumor-specific probe for human neoplastic B lymphocytes
M Wrightham, A L Tutt, M J Glennie, et al.
Blood
|
October 24, 2015
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo
Thomas R W Tipton, C Ian Mockridge, Ruth R French, et al.
Journal of Immunological Methods
|
June 16, 2010
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects
G Hampson, T H Ward, J Cummings, et al.
Page
of 6